
News|Articles|October 1, 2006
Pipeline Preview (October 2006)
Dalteparin (Fragmin, Pfizer) for the extended treatment of symptomatic venous thromboembolism (proximal deep vein thrombosis and/or pulmonary embolus) to prevent recurrent venous thromboembolism in patients with cancer
Advertisement
Recommendations for approval
Recommendations against approval
Nonapprovable designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Older drug could slash blood transfusions during surgeries | ASH 2025
2
Sanofi’s Qfitlia seems favorable for hemophilia with easier dosing and broad coverage | ASH 2025
3
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
4
Breakthrough treatments offer hope for melanoma patients
5




















































